Peptides
Dapiglutide
A dual GLP-1/GLP-2 candidate with an unsuccessful small weight trial and a sponsor-reported paused program.
Small human trial missed weight endpoint; animal gut-barrier research
Practical use
Reviewed practical notes
- Name both targets correctly
- This candidate targets GLP-1 and GLP-2.
- Keep separate trials separate
- Different designs and participants can produce different estimates.
- Avoid gut-healing claims
- Animal barrier findings do not establish clinical symptom relief or prevention of inflammatory disease.
Overview
Dapiglutide combines GLP-1 and GLP-2 receptor activity. GLP-2 is a different target from GIP, so it should not be described as another GLP-1/GIP combination. Its gut-barrier rationale is a hypothesis requiring its own clinical evidence.
Risks and limitations
Nausea and reduced appetite occurred in the small obesity trial. No discontinuations were attributed to drug adverse effects, but 54 people over 12 weeks cannot establish uncommon-event or long-term safety.
How to read this
The current Zealand Pharma pipeline page labels the program paused. The published investigator-led phase IIa trial and the sponsor’s separate phase 1b findings must be kept distinct; their different results are not interchangeable.
Research explained
Investigator-led obesity proof-of-concept trial
Who was studied
54 adults with obesity randomized to dapiglutide or placebo for 12 weeks without concurrent lifestyle intervention.
What was found
The primary comparison showed a placebo-adjusted weight change of −2.1% (95% CI −4.3 to 0.2; p=0.076), which was not statistically significant.
What it cannot establish
Small and short; a confidence interval crossing no difference does not establish meaningful weight reduction. It also does not prove that every possible formulation or study will fail.
Read the original studyIntestinal-barrier experiment
Who was studied
Mouse short-bowel-syndrome models and intestinal-barrier measurements.
What was found
The investigators observed effects on jejunal barrier-related proteins and permeability measures.
What it cannot establish
A surgically altered mouse intestine is not evidence that dapiglutide treats nonspecific gut symptoms or systemic inflammation in humans.
Read the original studyPaused is a current program state
Zealand attributes the pause to portfolio management. Its page reports a separate phase 1b program; those sponsor results do not change the negative primary result in the published 12-week investigator trial.
Supporting sourceSources
2026 human proof-of-concept trial
Zealand current paused-program page
Sources checked 2026-10-01.
General education; not a personal treatment plan.